Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.

Daly MB1, Pilarski R1, Axilbund JE1, Berry M1, Buys SS1, Crawford B1, Farmer M1, Friedman S1, Garber JE1, Khan S1, Klein C1, Kohlmann W1, Kurian A1,Litton JK1, Madlensky L1, Marcom PK1, Merajver SD1, Offit K1, Pal T1, Rana H1, Reiser G1, Robson ME1, Shannon KM1, Swisher E1, Voian NC1, Weitzel JN1,Whelan A1, Wick MJ1, Wiesner GL1, Dwyer M1, Kumar R1, Darlow S1.

Author information

Abstract

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling and risk assessment and management for hereditary cancer syndromes. Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer and are intended to assist with clinical and shared decision-making. These NCCN Guidelines Insights summarize major discussion points of the 2015 NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meeting. Major discussion topics this year included multigene testing, risk management recommendations for less common genetic mutations, and salpingectomy for ovarian cancer risk reduction. The panel also discussed revisions to genetic testing criteria that take into account ovarian cancer histology and personal history of pancreatic cancer.